TY - JOUR
T1 - The cut of the clot(h)
T2 - Snake venom fibrinogenases as therapeutic agents
AU - Gardiner, E. E.
AU - Andrews, Robert K.
PY - 2008/8
Y1 - 2008/8
N2 - Recent reports on outcomes of clinical trials assessing Viprinex (Ancrod) in the treatment of ischemic stroke [1,2] highlight the re-emerging interest in snake venom serine proteases as therapeutics. In this issue, Paes Leme and colleagues [3] describe a serine protease, Bothrops protease A (BPA) that selectively targets fibrinogen, illustrating the ongoing development of these agents as anti-thrombotics
AB - Recent reports on outcomes of clinical trials assessing Viprinex (Ancrod) in the treatment of ischemic stroke [1,2] highlight the re-emerging interest in snake venom serine proteases as therapeutics. In this issue, Paes Leme and colleagues [3] describe a serine protease, Bothrops protease A (BPA) that selectively targets fibrinogen, illustrating the ongoing development of these agents as anti-thrombotics
UR - http://www.scopus.com/inward/record.url?scp=47649090828&partnerID=8YFLogxK
U2 - 10.1111/j.1538-7836.2008.03057.x
DO - 10.1111/j.1538-7836.2008.03057.x
M3 - Comment/debate
SN - 1538-7933
VL - 6
SP - 1360
EP - 1362
JO - Journal of Thrombosis and Haemostasis
JF - Journal of Thrombosis and Haemostasis
IS - 8
ER -